Vasodilator Therapy in Hypertension

Carthy, E. Paul Mac

doi:10.1111/j.1527-3466.1990.tb00437.x

Cited by 4 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the past decades, the treatment of systemic arterial hypertension with vasodilating drugs has become one of the focal points of pharmacotherapy (28,35). This development is based on the rationale that the pathophysiology of an established hypertension is characterized predominantly by an increased peripheral vascular resistance (10).…”

Section: Introductionmentioning

confidence: 99%

“…A number of vasodilating drugs with very different pharmacological profiles have been developed. Examples are nonspecific vasodilators such as (di)hydralazine (35), cadralazine (37) and sodium nitroprusside (35); calcium channel blockers (13,16) such as nifedipine (a dihydropyridine), verapamil and diltiazem; angiotensin converting enzyme inhibitors, such as captopril and enalapril; a1 adrenoceptor blockers such as prazosin and urapidil (7,32,75); and potassium channel openers, such as pinacidil (1 1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Naftopidil, A Novel Antihypertensive Drug

Himmel

1994

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Naftopidil, A Novel Antihypertensive Drug

Himmel

1994

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Cardiovascular Agents

Cervoni¹,

Crandall²,

Chan³

2000

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

The six primary classes of cardiovascular drugs, ie, antiarrhythmic agents, antianginal agents, agents used in the treatment of congestive heart failure, antiatherosclerotic agents, antihypertensive agents, and thrombolytic agents, are reviewed. An overview of the physiology of the cardiovascular system is presented for each class together with the pathology of the system leading to specific cardiovascular disorders. The mechanism(s) of action of the cardiovascular agents are discussed when known, and the principal actions of the cardiovascular agents that contribute to amelioration of the underlying pathology of the cardiovascular disease are reviewed. Side effects and toxicities of the cardiovascular agents are also presented. Drugs clinically in use and some of those drugs under development are discussed. A brief review of the current and projected sales of ethical pharmaceuticals is presented in relation to the sales of cardiovascular agents which is the fastest growing segment of the ethical pharmaceutical market.

show abstract

Cardiovascular Agents

Joshi

Burnett

2003

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Cardiovascular disease still remains the nation's number one killer of men and women of all races, in spite of tremendous advances in basic and clinical research greatly helping to improve the prevention, treatment, and mortality of heart disease. It is estimated that ∼40% of Americans (∼60 million between the ages of 40–70) suffer from some degree of this disease. The problem of treating heart diseases has been at the forefront of the international medical community, and the cardiovascular drug market has been leading the drug discovery efforts in sales for the past two decades. A constant flow of new and effective drugs has kept this sector in its number one position and will continue to do so in the future. The development of unique, novel, and tissue specific cardiac drugs to replace or supplement existing therapies for various cardiac disorders continues to generate significant and growing attention. This has evolved hand‐in‐hand with research that has facilitated a better understanding of the underlying causes of cardiac disease states. The first draft of the human genome map is a turning point in the research for new medicines that will address the cause, versus the symptoms, of many human ailments including cardiovascular diseases. This article focuses on the review of past treatments, significant new developments, and future therapies for the treatment of various cardiovascular diseases. The article is divided into six sections: antiarrhythmic agents, antianginal agents, antihypertensive agents, antilipemic agents, antithrombolytic agents, and other therapeutics. Each section is further discussed in depth as per the classification of agents based upon their mechanism of action and clinical application. This article is designed primarily to serve the needs of a wide audience.

show abstract

Vasodilator Therapy in Hypertension

Cited by 4 publications

References 56 publications

Naftopidil, A Novel Antihypertensive Drug

Naftopidil, A Novel Antihypertensive Drug

Cardiovascular Agents

Cardiovascular Agents

Contact Info

Product

Resources

About